Luo Rong-cheng, Li Ai-min, Zhang Jun-yi, Liao Wang-jun, Ji Chen-yang, Miao Jing-xia
Department of Oncology, Nanfang Hospital, The First Military Medical University, Guangzhou 510515, China.
Zhonghua Zhong Liu Za Zhi. 2004 Jan;26(1):52-4.
To investigate the efficacy and toxicity of recombinant humanized anti-Her-2/neu antibody (Herceptin) and Taxol for patients with Her-2/neu overexpressing metastatic breast cancer.
Sixty patients with Her-2/neu overexpressing metastatic breast cancer were investigated. Of the 60 cases, 22 were treated with Herceptin and Taxol and 38 with Taxol and doxorubicin.
The total response rate (RR) of Herceptin and Taxol was 68.2%, and that of Taxol and doxorubicin was 44.7%. The RR of patients with Her-2/neu(+++) was 75%, while that of patients with Her-2/neu(++) was 50%. The major adverse effects were gastro-intestinal tract reactions, myopathy, bone marrow suppression and alopecia.
The treatment with Herceptin and Taxol is effective and safe for patients with Her-2/neu overexpressing metastatic breast cancer. The therapeutic effect is related to the degree of Her-2/neu overexpression.
探讨重组人源化抗Her-2/neu抗体（赫赛汀）与紫杉醇联合应用于Her-2/neu过表达转移性乳腺癌患者的疗效和毒性。
对60例Her-2/neu过表达转移性乳腺癌患者进行研究。60例患者中，22例接受赫赛汀与紫杉醇治疗，38例接受紫杉醇与阿霉素治疗。
赫赛汀与紫杉醇联合治疗的总有效率（RR）为68.2%，紫杉醇与阿霉素联合治疗的总有效率为44.7%。Her-2/neu（+++）患者的RR为75%，而Her-2/neu（++）患者的RR为50%。主要不良反应为胃肠道反应、肌病、骨髓抑制和脱发。
赫赛汀与紫杉醇联合治疗对Her-2/neu过表达转移性乳腺癌患者有效且安全。治疗效果与Her-2/neu过表达程度有关。
